Review



u937 cells  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    DSMZ u937 cells
    U937 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 366 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42976223-221-0-2
    Average 96 stars, based on 366 article reviews
    u937 cells - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Multiplex Assay:

    Article Title: ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.
    Article Snippet: .. Cell lines THP1, NOMO1, K562, MOLM16, MV4-11, U937, and HEK293T were obtained from DSMZ and continuously tested for mycoplasma and cross-contamination by Multiplex Cell Authentication (Multiplexion, Heidelberg, Germany). ..

    Cell Culture:

    Article Title: Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1 mediated chronic inflammatory skin diseases.
    Article Snippet: .. Culture and necroptosis assay of U937 and L929 cells Human monocytic leukemia U937 cells (DSMZ, ACC 5) were cultured in RPMI 1640 medium (Gibco, 72400-021) without Phenol Red and supplemented with 10 % fetal bovine serum at 37 °C and 5 % CO2. .. Mouse NCTC clone 929 (L cell, L929) cells (ATCC, CLL1) were cultured in DMEM/F12 + 15 mM HEPES + L-glutamin medium (Gibco, 11330-032) supplemented with 10 % heat inactivated FBS (Sigma, F4135), 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C and 5 % CO2.

    Article Title: The EAAT1 aspartate/glutamate transporter is dispensable for acute myeloid leukemia cell growth and response to therapy
    Article Snippet: Both cell models were cultured at 37°C in a humidified incubator with ambient air and 5% CO 2 in RPMI1640 medium (ThermoFisher, 31870074) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich, F7524), 100 I.U./mL penicillin-100 μg/mL streptomycin (ThermoFisher, 15140122), 2 mM L-glutamine (Fisher Scientific, 11510626), 20 ng/mL recombinant mouse stem cell factor, 10 ng/mL recombinant mouse interleukin 3 and 10 ng/mL recombinant mouse interleukin 6 (BioLegend Europe BV, 579708, 575708, 575508). .. U937, NB4, MV4–11, MOLM14, OCI-AML3, NOMO-1 and MONOMAC6 (MM6) human AML cell lines were obtained from the Leibniz Institute DSMZ and cultured at 37°C in a humidified incubator with ambient air and 5% CO 2 in RPMI1640 medium supplemented with 10% FBS, 100 I.U./mL penicillin-100 μg/mL streptomycin and 2 mM L-glutamine. .. Cell line identity was validated by DNA fingerprinting and cultures were tested for mycoplasma contamination every six months using a Mycoplasma PCR Detection Kit (Abcam, ab289834).

    Article Title: The EAAT1 aspartate/glutamate transporter is dispensable for acute myeloid leukemia cell growth and response to therapy.
    Article Snippet: Both cell models were cultured at 37°C in a humidified incubator with ambient air and 5% CO 2 in RPMI1640 medium (ThermoFisher, 31870074) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich, F7524), 100 I.U./mL penicillin-100 μg/mL streptomycin (ThermoFisher, 15140122), 2 mM L-glutamine (Fisher Scientific, 11510626), 20 ng/mL recombinant mouse stem cell factor, 10 ng/mL recombinant mouse interleukin 3 and 10 ng/mL recombinant mouse interleukin 6 (BioLegend Europe BV, 579708, 575708, 575508). .. U937, NB4, MV4–11, MOLM14, OCI-AML3, NOMO-1 and MONOMAC6 (MM6) human AML cell lines were obtained from the Leibniz Institute DSMZ and cultured at 37°C in a humidified incubator with ambient air and 5% CO 2 in RPMI1640 medium supplemented with 10% FBS, 100 I.U./mL penicillin-100 μg/mL streptomy- cin and 2 mM L-glutamine. .. Cell line identity was validated by DNA fingerprinting and cultures were tested for mycoplasma contamination every six months using a Mycoplasma PCR Detection Kit (Abcam, ab289834).

    other:

    Article Title: METTL16 inhibitors and uses thereof
    Article Snippet: U937, HEL, THP1, K562, MV4-11, RS4-11 and SUP-B15 were purchased from the American Type Culture Collection, and NOMO-1, ML-2, NB4 and MONOMAC-6 were obtained from DSMZ.

    Article Title: ΔNp73 isoform defines a TP53 -mutant-like poor-risk subgroup of acute myeloid leukemia
    Article Snippet: U937 (male origin) , DSMZ , ACC 5.

    Activity Assay:

    Article Title: An Imidazo[2,1‐b][1,3,4]thiadiazole Derivative Inhibits the Virulence Factor α‐Hemolysin by Blocking the Pullout of Its Stem Domain
    Article Snippet: .. Initially, different cell lines, A549 (DSMZ #ACC107), L929 (DSMZ #ACC2), KB3.1 (DSMZ #ACC158), RAW 264.7 (ATCC #TIB‐71), and U937 (DSMZ #ACC5), were tested in the assay for Hla activity, following which U937 cells were selected for further assay optimization. ..



    Similar Products

    u937  (ATCC)
    99
    ATCC u937
    U937, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42998252-237-8-18
    Average 99 stars, based on 1 article reviews
    u937 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    DSMZ u937 cells
    U937 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42976223-221-0-2
    Average 96 stars, based on 1 article reviews
    u937 cells - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    99
    ATCC genetic manipulation u937 cells
    Genetic Manipulation U937 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42966766-223-3-7
    Average 99 stars, based on 1 article reviews
    genetic manipulation u937 cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC monocyte cell line u937
    A Replication in the CureGN study: the bar plots showing that 26 of the 28 (93%) prioritized disease MRs exhibited increased activity in the CureGN replication cohort (123 cases and 1300 disease controls) compared to the discovery cohort; the P -value is unadjusted and based on a one-sided test. B The top panel depicts the ranking of the 28 active MRs by their normalized enrichment score (NES) based on the original comparison of 255 cases and 38 healthy controls (discovery), while the bottom panel shows the corresponding NES based on the CureGN cohort (replication). C Validations by in vitro studies: the bar plots depicting 22 out of the 28 MRs were activated by polymeric IgA1 stimulation of <t>U937</t> monocytes, and 22 of the 28 MRs’ activities were reversed by adding the SHIP-1 activator alongside polymeric IgA1. The P -value is unadjusted and based on a one-sided test. D The top panel depicts the ranking of the 28 MRs by their NES based on the comparison of the U937 monocyte cell line stimulated with polymeric IgA1compared to control, while the bottom panel shows the corresponding NES after exposure to polymeric IgA1 with AQX-1125 compared to polymeric IgA1 alone; 22 of 28 MRs demonstrated the expected reversed pattern of activation with AQX-1125 treatment.
    Monocyte Cell Line U937, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pmc13754909-463-0-4
    Average 99 stars, based on 1 article reviews
    monocyte cell line u937 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC u937 cells
    A Replication in the CureGN study: the bar plots showing that 26 of the 28 (93%) prioritized disease MRs exhibited increased activity in the CureGN replication cohort (123 cases and 1300 disease controls) compared to the discovery cohort; the P -value is unadjusted and based on a one-sided test. B The top panel depicts the ranking of the 28 active MRs by their normalized enrichment score (NES) based on the original comparison of 255 cases and 38 healthy controls (discovery), while the bottom panel shows the corresponding NES based on the CureGN cohort (replication). C Validations by in vitro studies: the bar plots depicting 22 out of the 28 MRs were activated by polymeric IgA1 stimulation of <t>U937</t> monocytes, and 22 of the 28 MRs’ activities were reversed by adding the SHIP-1 activator alongside polymeric IgA1. The P -value is unadjusted and based on a one-sided test. D The top panel depicts the ranking of the 28 MRs by their NES based on the comparison of the U937 monocyte cell line stimulated with polymeric IgA1compared to control, while the bottom panel shows the corresponding NES after exposure to polymeric IgA1 with AQX-1125 compared to polymeric IgA1 alone; 22 of 28 MRs demonstrated the expected reversed pattern of activation with AQX-1125 treatment.
    U937 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42864442-313-5-23
    Average 99 stars, based on 1 article reviews
    u937 cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human pro monocytic cell line u937
    A Replication in the CureGN study: the bar plots showing that 26 of the 28 (93%) prioritized disease MRs exhibited increased activity in the CureGN replication cohort (123 cases and 1300 disease controls) compared to the discovery cohort; the P -value is unadjusted and based on a one-sided test. B The top panel depicts the ranking of the 28 active MRs by their normalized enrichment score (NES) based on the original comparison of 255 cases and 38 healthy controls (discovery), while the bottom panel shows the corresponding NES based on the CureGN cohort (replication). C Validations by in vitro studies: the bar plots depicting 22 out of the 28 MRs were activated by polymeric IgA1 stimulation of <t>U937</t> monocytes, and 22 of the 28 MRs’ activities were reversed by adding the SHIP-1 activator alongside polymeric IgA1. The P -value is unadjusted and based on a one-sided test. D The top panel depicts the ranking of the 28 MRs by their NES based on the comparison of the U937 monocyte cell line stimulated with polymeric IgA1compared to control, while the bottom panel shows the corresponding NES after exposure to polymeric IgA1 with AQX-1125 compared to polymeric IgA1 alone; 22 of 28 MRs demonstrated the expected reversed pattern of activation with AQX-1125 treatment.
    Human Pro Monocytic Cell Line U937, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/u937/U-937/pm42843443-51-7-13
    Average 99 stars, based on 1 article reviews
    human pro monocytic cell line u937 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    Image Search Results


    A Replication in the CureGN study: the bar plots showing that 26 of the 28 (93%) prioritized disease MRs exhibited increased activity in the CureGN replication cohort (123 cases and 1300 disease controls) compared to the discovery cohort; the P -value is unadjusted and based on a one-sided test. B The top panel depicts the ranking of the 28 active MRs by their normalized enrichment score (NES) based on the original comparison of 255 cases and 38 healthy controls (discovery), while the bottom panel shows the corresponding NES based on the CureGN cohort (replication). C Validations by in vitro studies: the bar plots depicting 22 out of the 28 MRs were activated by polymeric IgA1 stimulation of U937 monocytes, and 22 of the 28 MRs’ activities were reversed by adding the SHIP-1 activator alongside polymeric IgA1. The P -value is unadjusted and based on a one-sided test. D The top panel depicts the ranking of the 28 MRs by their NES based on the comparison of the U937 monocyte cell line stimulated with polymeric IgA1compared to control, while the bottom panel shows the corresponding NES after exposure to polymeric IgA1 with AQX-1125 compared to polymeric IgA1 alone; 22 of 28 MRs demonstrated the expected reversed pattern of activation with AQX-1125 treatment.

    Journal: Nature Communications

    Article Title: Genome-wide studies define genetic mechanisms of IgA vasculitis

    doi: 10.1038/s41467-026-78026-6

    Figure Lengend Snippet: A Replication in the CureGN study: the bar plots showing that 26 of the 28 (93%) prioritized disease MRs exhibited increased activity in the CureGN replication cohort (123 cases and 1300 disease controls) compared to the discovery cohort; the P -value is unadjusted and based on a one-sided test. B The top panel depicts the ranking of the 28 active MRs by their normalized enrichment score (NES) based on the original comparison of 255 cases and 38 healthy controls (discovery), while the bottom panel shows the corresponding NES based on the CureGN cohort (replication). C Validations by in vitro studies: the bar plots depicting 22 out of the 28 MRs were activated by polymeric IgA1 stimulation of U937 monocytes, and 22 of the 28 MRs’ activities were reversed by adding the SHIP-1 activator alongside polymeric IgA1. The P -value is unadjusted and based on a one-sided test. D The top panel depicts the ranking of the 28 MRs by their NES based on the comparison of the U937 monocyte cell line stimulated with polymeric IgA1compared to control, while the bottom panel shows the corresponding NES after exposure to polymeric IgA1 with AQX-1125 compared to polymeric IgA1 alone; 22 of 28 MRs demonstrated the expected reversed pattern of activation with AQX-1125 treatment.

    Article Snippet: Monocyte cell line U937 (American Type Culture Collection, ATCC, Rockville, MD, USA) was grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics .

    Techniques: Activity Assay, Comparison, In Vitro, Control, Activation Assay